LONDON (Reuters) – GlaxoSmithKline Plc (GSK) has stopped a high-profile clinical trial using a novel vaccine to fight lung cancer after deciding it will not be possible to find a sub-group of patients who might benefit.
The decision comes less than two weeks after GSK said the MAGE-A3 therapeutic vaccine did not help patients with non-small cell lung cancer in the Phase III study overall, but it was still looking for improvements among patients with a particular genetic profile.
(Reuters) – Drugmaker GlaxoSmithKline (GSK.L: Quote, Profile, Research) plans to invest up to 130 million pounds in Africa over the next five years as chronic diseases become more common among the continent’s swelling urban middle classes.
The decision reflects the draw for the pharmaceutical industry of the region’s rapid economic growth and rising demand for treatments for non-communicable diseases (NCDs) like heart and lung disorders, diabetes and cancer.
(Reuters) – Drugmaker GlaxoSmithKline plans to invest up to 130 million pounds ($216 million) in Africa over the next five years as it bets on the importance of the continent in driving long-term demand for medicine.
The decision reflects the pharmaceutical industry’s growing interest in Africa, given improved economic growth and rising demand for treatments against chronic diseases that are becoming more common among urban middle classes.
CAMBRIDGE, England (Reuters) – AstraZeneca, which will complete its move to Cambridge by 2016, is already putting down roots in the ecosystem of the university city as it seeks to revitalize its drug research.
Britain’s second-biggest pharmaceuticals group said on Monday it had struck an unique deal with the state-funded Medical Research Council (MRC) under which academic scientists will work alongside its staff at its new Cambridge site.
LONDON, March 27 (Reuters) – Britain’s healthcare agency
NICE, which determines the use of treatments in the state-run
health service, may be more likely to say ‘yes’ to new drugs
under proposals that enable it to take a broader view of the
value they offer.
The National Institute for Health and Clinical Excellence
(NICE), will in future look at the “wider societal impact” of
therapies – whether they enable a patient to go back to work
faster, for example, for the wider benefit of society – as well
as their cost-effectiveness on more limited clinical grounds.